CymaBay Therapeutics

147 articles about CymaBay Therapeutics

• CymaBay Therapeutics Receives $5M Milestone Payment for Arhalofenate From Kowa Pharmaceuticals America

  1/8/2018

  The two companied inked the deal in December 2016.

• CymaBay Therapeutics Strengthens Management Team With Appointment of Paul Quinlan as General Counsel

  12/4/2017

  As CymaBay’s chief legal officer, he will be responsible for all legal affairs, including providing legal advice to CymaBay’s Board of Directors and senior management.

• CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates

  11/9/2017

  Conference call today at 4:30pm EST.

• CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8

  11/1/2017

  The company will host a conference call and live audio webcast on Wednesday, November 8, 2017 at 4:30 p.m. ET.

• CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer

  10/31/2017

  Mr. Shah has been serving as the Interim President and Chief Executive Officer since March 2017.

• CymaBay Therapeutics Announces Oral Late-Breaking Presentation Of Interim Results From An Ongoing Phase 2 Study Of Patients With Primary Biliary Cholangitis At The American Association for Study of Liver Diseases 2017 Liver Meeting

  10/9/2017

• CymaBay Therapeutics Granted EMA Orphan Drug Designation For Seladelpar For The Treatment Of Primary Biliary Cholangitis

  9/11/2017

• CymaBay Therapeutics Announces The Publication Of The Seladelpar Proof-Of-Concept Study For Primary Biliary Cholangitis In Lancet Gastroenterology And Hepatology

  8/15/2017

• CymaBay Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

  8/11/2017

• CymaBay Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 10

  8/7/2017

• CymaBay Therapeutics Announces Positive Interim Results From Its Ongoing Low-Dose Phase II Study Of Seladelpar In Patients With Primary Biliary Cholangitis

  7/17/2017

• CymaBay Therapeutics Announces The Appointment Of Klara Dickinson As Senior Vice President, Regulatory Affairs And Quality Assurance And The Promotion Of Daniel Menold To Vice President, Finance

  6/26/2017

• CymaBay Therapeutics Reports First Quarter 2017 Financial Results And Provides Corporate Update

  5/12/2017

• CymaBay Therapeutics To Report First Quarter 2017 Financial Results On Thursday, May 11

  5/4/2017

• Bay Area's CymaBay Therapeutics CEO To Retire, Interim Leader Named

  3/29/2017

• Kowa Pharmaceuticals America Announces Agreement With CymaBay Therapeutics To License Gout Compound

  1/4/2017

• CymaBay Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results

  3/30/2016

• CymaBay Therapeutics To Present At The Biotech Showcase 2016

  1/6/2016

• CymaBay Therapeutics Announces Participation At Three Upcoming Investor Conferences

  11/16/2015

• CymaBay Therapeutics Announces The Initiation Of A Phase II Study Of MBX-8025 In Patients With Primary Biliary Cholangitis/Cirrhosis

  11/10/2015